IL290798A - Prodrugs of the tyrosine kinase inhibitor for treating cancer - Google Patents
Prodrugs of the tyrosine kinase inhibitor for treating cancerInfo
- Publication number
- IL290798A IL290798A IL290798A IL29079822A IL290798A IL 290798 A IL290798 A IL 290798A IL 290798 A IL290798 A IL 290798A IL 29079822 A IL29079822 A IL 29079822A IL 290798 A IL290798 A IL 290798A
- Authority
- IL
- Israel
- Prior art keywords
- prodrugs
- tyrosine kinase
- kinase inhibitor
- treating cancer
- cancer
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 229940002612 prodrug Drugs 0.000 title 1
- 239000000651 prodrug Substances 0.000 title 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 title 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 title 1
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910818675.XA CN112442010B (en) | 2019-08-30 | 2019-08-30 | Prodrug compounds and application thereof in treating cancers |
CN201910817505.XA CN112442009B (en) | 2019-08-30 | 2019-08-30 | Deuterated compounds and their use for treating cancer |
CN201910818779.0A CN112442011B (en) | 2019-08-30 | 2019-08-30 | Prodrug compound and application thereof in treating cancers |
US202062994364P | 2020-03-25 | 2020-03-25 | |
PCT/CA2020/051177 WO2021035360A1 (en) | 2019-08-30 | 2020-08-28 | Prodrugs of the tyrosine kinase inhibitor for treating cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
IL290798A true IL290798A (en) | 2022-04-01 |
Family
ID=74684795
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL290798A IL290798A (en) | 2019-08-30 | 2022-02-22 | Prodrugs of the tyrosine kinase inhibitor for treating cancer |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP4021912A4 (en) |
AU (1) | AU2020338490A1 (en) |
CA (1) | CA3147801A1 (en) |
IL (1) | IL290798A (en) |
WO (1) | WO2021035360A1 (en) |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PE20010306A1 (en) * | 1999-07-02 | 2001-03-29 | Agouron Pharma | INDAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM USEFUL FOR THE INHIBITION OF PROTEIN KINASE |
CN106336397A (en) * | 2015-07-07 | 2017-01-18 | 郭明山 | Novel compound for treating ophthalmic diseases |
CN106317017A (en) * | 2015-07-10 | 2017-01-11 | 李建成 | Novel compound used for treating ophthalmic diseases |
CN106478596A (en) * | 2015-08-25 | 2017-03-08 | 李建成 | A kind of noval chemical compound as treatment ophthalmic diseasess |
CA3096963A1 (en) * | 2018-04-13 | 2019-10-17 | Hinova Pharmaceuticals Inc. | A new method for synthesis of deuterated amide and deuterated sulfonamide |
-
2020
- 2020-08-28 CA CA3147801A patent/CA3147801A1/en active Pending
- 2020-08-28 WO PCT/CA2020/051177 patent/WO2021035360A1/en unknown
- 2020-08-28 EP EP20857153.9A patent/EP4021912A4/en active Pending
- 2020-08-28 AU AU2020338490A patent/AU2020338490A1/en active Pending
-
2022
- 2022-02-22 IL IL290798A patent/IL290798A/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP4021912A4 (en) | 2023-08-23 |
AU2020338490A1 (en) | 2022-03-17 |
WO2021035360A1 (en) | 2021-03-04 |
EP4021912A1 (en) | 2022-07-06 |
CA3147801A1 (en) | 2021-03-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3781564C0 (en) | Pyridazine derivatives for the treatment of cancer | |
EP3758706A4 (en) | Wee1 kinase inhibitors and methods of treating cancer using the same | |
EP4079735A4 (en) | Compound for inhibiting and inducing degradation of egfr kinase | |
IL280158A (en) | Methods of treating cancer with pi3k inhibitor, gdc-0077 | |
EP3226869A4 (en) | Kinase inhibitor prodrug for the treatment of cancer | |
EP3500257A4 (en) | Kinase inhibitor compounds, compositions, and methods of treating cancer | |
IL287907A (en) | Methods for treating cancer | |
IL284856A (en) | A dbait molecule in combination with kinase inhibitor for the treatment of cancer | |
EP4081527A4 (en) | The combination of cyclin dependent kinase 7 inhibitor and immunotherapy for treatment of cancer | |
IL308195A (en) | Ras inhibitors for the treatment of cancer | |
IL287115A (en) | Compounds against cancer bearing tyrosine kinase inhibitor resistant egfr mutations | |
IL283659A (en) | Methods for treating cancer resistant to cdk4/6 inhibitors | |
EP4108666A4 (en) | Multi-target tyrosine kinase inhibitor | |
IL288522A (en) | Egfr inhibitor for the treatment of cancer | |
EP3630080A4 (en) | Use of ezh2 inhibitors for treating cancer | |
EP3966208A4 (en) | Compounds and methods for treating cancer | |
SG11202107017TA (en) | Methods of treating cancer | |
IL286727A (en) | Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma | |
IL291424A (en) | Use of dkk-1 inhibitors for treating cancer | |
EP3843773A4 (en) | Inhibition of rip kinases for treating neurodegenerative disorders | |
IL288665A (en) | Methods of treating cancer using prmt5 inhibitors | |
IL283885A (en) | Cxcr7 inhibitors for the treatment of cancer | |
SG10201909596RA (en) | Synthesis of Tyrosine Kinase Inhibitors | |
GB201909468D0 (en) | Compounds for treating cancer | |
EP3774799C0 (en) | Nek6 kinase inhibitors useful for the treatment of solid tumors |